Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 April 2021
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Melanoma Institute Australia and Melanoma Patients Australia are partnering to develop the country’s first ever landmark melanoma report: State of the Nation – A Report into Melanoma.
This comprehensive report will examine the issues currently facing melanoma patients and carers across Australia and make recommendations for policy change and investment to substantially improve outcomes for them as well as the wider Australian community.
‘Australia has the highest melanoma rates in the world, and this State of the Nation report will for the first times provide an indepth assessment of the far-reaching impacts of the disease across the country,’ said Melanoma Institute Australia CEO Matthew Browne.
‘It will provide the opportunity to revolutionise melanoma policy, funding, care and support services going forward, which will in the long term benefit all Australians for generations to come.’
Critical to developing State of the Nation- A Report into Melanoma is input from melanoma patients and their carers from across Australia. This is a call to action and we are asking people to take part in an online survey so we can understand their personal experiences.
‘The survey will provide invaluable insights into the impact of melanoma and the realities faced by patients and their families,’ said Melanoma Patients Australia CEO Victoria Beedle.
‘Your feedback is critical to the success of this State of the Nation report and I urge all melanoma patients and their families to invest just half an hour in completing this survey. By doing so, you will become part of the solution to this huge problem impacting communities across the country.’
Key areas being addressed in State of the Nation- A Report into Melanoma include:
- melanoma prevention and awareness, including the effectiveness of current campaigns and what more needs to be done
- early detection and diagnosis including the feasibility of a national skin screening program
- treatment options available and access to breakthrough therapies
- supportive care services during and after treatment
- issues facing survivors and their families after successful treatment
- palliative and end of life care
- research priorities, opportunities and challenges.
The State of the Nation report will be presented to government mid-year with the aim of guiding future policy and funding direction to help reduce the impact of melanoma on Australian society.
‘Every 30 minutes another Australian is told they have melanoma – so in the time it takes you to do the survey, another family will be embarking on the daunting and frightening melanoma journey,’ Matthew Browne added.
‘Completing the survey is a small investment of time with a potentially life-changing impact, and I thank all our wonderful melanoma community for stepping up to help.’
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.